CD8A and neoplasm: Supporting the mechanistic findings mentioned above, IF analysis of tumor tissues revealed that SFN combined with anti-CTLA-4 led to an increase in CD8+ CTL population and GB release levels compared to monotherapy (Fig. 7D–F).